They don't, they're not going to do that part
Current UK guidance (NICE NG226 and NOGG 2024) recommends fracture risk assessment using tools such as FRAX or QFracture for at-risk populations, with subsequent DXA scanning if indicated by risk thresholds
Your clinician needs the real picture to adjust the plan
Obesity is a chronic disease that needs lifelong care and is best treated with long-term GLP-1 use combined with a structured program that includes healthy eating, regular movement and ongoing counseling to lose and maintain weight loss, according to the WHO
Semaglutide and liraglutide may reduce alcohol consumption in individuals with AUD owenhaskins Nov 14, 2024 2 min read A joint study by the University of Eastern Finland and Karolinska Institutet in Sweden has found that the GLP-1 agonists semaglutide and liraglutide, which are used for treating diabetes and obesity, were associated with fewer hospitalisations among individuals with alcohol use disorder (AUD)
The graph makes the week easier to read
